Form 4: Amylyx Pharmaceuticals Chief Medical Officer Sells Shares to Cover Tax Obligations

Amylyx Pharmaceuticals' Chief Medical Officer, Camille L. Bedrosian, sold 5,421 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Camille L. Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals, sold 5,421 shares of common stock on December 2, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $5.5354, with individual transaction prices ranging from $5.475 to $5.59.
• Following the transaction, Ms. Bedrosian directly owns 138,380 shares of Amylyx Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document describes a routine transaction for tax purposes, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine transaction for company insiders to manage their tax obligations related to stock-based compensation. It is common for executives to sell shares to cover taxes when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the pharmaceutical industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar transactions by executives at other firms.
• The sale of 5,421 shares is not unusual for an executive at a company of Amylyx's size.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is not expected to be significant.

Key Dates

Keywords

Amylyx Pharmaceuticals, insider trading, stock sale, Camille L. Bedrosian, restricted stock units, tax obligations, AMLX, Chief Medical Officer